DK3394046T3 - Cftr-regulatorer og fremgangsmåder til anvendelse deraf - Google Patents
Cftr-regulatorer og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK3394046T3 DK3394046T3 DK16880159.5T DK16880159T DK3394046T3 DK 3394046 T3 DK3394046 T3 DK 3394046T3 DK 16880159 T DK16880159 T DK 16880159T DK 3394046 T3 DK3394046 T3 DK 3394046T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- cftr
- regulators
- cftr regulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562387579P | 2015-12-24 | 2015-12-24 | |
US201662376808P | 2016-08-18 | 2016-08-18 | |
PCT/US2016/068566 WO2017112950A1 (en) | 2015-12-24 | 2016-12-23 | Cftr regulators and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3394046T3 true DK3394046T3 (da) | 2022-04-04 |
Family
ID=59091221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16880159.5T DK3394046T3 (da) | 2015-12-24 | 2016-12-23 | Cftr-regulatorer og fremgangsmåder til anvendelse deraf |
Country Status (18)
Country | Link |
---|---|
US (2) | US11084795B2 (da) |
EP (2) | EP4071140A1 (da) |
JP (2) | JP6938509B2 (da) |
KR (1) | KR20180101416A (da) |
CN (1) | CN108699040B (da) |
AU (1) | AU2016377785B2 (da) |
BR (1) | BR112018012934B1 (da) |
CA (1) | CA3009534A1 (da) |
CL (1) | CL2018001716A1 (da) |
CO (1) | CO2018007236A2 (da) |
DK (1) | DK3394046T3 (da) |
ES (1) | ES2913051T3 (da) |
IL (1) | IL260212B (da) |
PL (1) | PL3394046T3 (da) |
PT (1) | PT3394046T (da) |
RU (1) | RU2730855C2 (da) |
WO (1) | WO2017112950A1 (da) |
ZA (1) | ZA201804229B (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180101416A (ko) * | 2015-12-24 | 2018-09-12 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Cftr 조절제 및 이의 이용 방법 |
AU2016379444B2 (en) | 2015-12-24 | 2021-04-29 | The Regents Of The University Of California | CFTR regulators and methods of use thereof |
KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0008864A1 (en) | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
ZA794209B (en) * | 1978-08-15 | 1980-07-30 | Fisons Ltd | Pharmaceutically active heterocyclic compounds |
US4181724A (en) | 1978-09-11 | 1980-01-01 | The Upjohn Company | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
FR2653430B1 (fr) | 1989-10-23 | 1991-12-20 | Pf Medicament | Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique. |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
AU5433594A (en) | 1992-11-19 | 1994-06-08 | Dainippon Pharmaceutical Co. Ltd. | 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
HUP0101470A3 (en) * | 1998-03-31 | 2002-09-30 | Warner Lambert Co | Quinoxalinones as serine protease inhibitors such as factor xa and thrombin and medicaments containing the compounds |
DE102004023332A1 (de) | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
ES2537803T3 (es) | 2007-05-22 | 2015-06-12 | Astellas Pharma Inc. | Compuesto de tetrahidroisoquinolina 1-sustituida |
JP5618837B2 (ja) | 2008-03-05 | 2014-11-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | インスリン分泌刺激剤としてのキノキサリノン誘導体、それらを得る方法および糖尿病を治療するためのそれらの使用 |
CA2742042A1 (en) * | 2008-10-23 | 2010-04-29 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
MX2015007940A (es) | 2012-12-19 | 2016-03-11 | Novartis Ag | Compuestos tricíclicos como inhibidores de cftr. |
WO2015168079A1 (en) * | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
KR20180101416A (ko) | 2015-12-24 | 2018-09-12 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Cftr 조절제 및 이의 이용 방법 |
-
2016
- 2016-12-23 KR KR1020187021223A patent/KR20180101416A/ko not_active Application Discontinuation
- 2016-12-23 US US16/016,281 patent/US11084795B2/en active Active
- 2016-12-23 AU AU2016377785A patent/AU2016377785B2/en active Active
- 2016-12-23 RU RU2018126957A patent/RU2730855C2/ru active
- 2016-12-23 EP EP22159301.5A patent/EP4071140A1/en active Pending
- 2016-12-23 CN CN201680082473.8A patent/CN108699040B/zh active Active
- 2016-12-23 ES ES16880159T patent/ES2913051T3/es active Active
- 2016-12-23 BR BR112018012934-8A patent/BR112018012934B1/pt active IP Right Grant
- 2016-12-23 PT PT168801595T patent/PT3394046T/pt unknown
- 2016-12-23 CA CA3009534A patent/CA3009534A1/en active Pending
- 2016-12-23 JP JP2018533117A patent/JP6938509B2/ja active Active
- 2016-12-23 DK DK16880159.5T patent/DK3394046T3/da active
- 2016-12-23 PL PL16880159T patent/PL3394046T3/pl unknown
- 2016-12-23 WO PCT/US2016/068566 patent/WO2017112950A1/en active Application Filing
- 2016-12-23 EP EP16880159.5A patent/EP3394046B1/en active Active
-
2018
- 2018-06-21 IL IL260212A patent/IL260212B/en unknown
- 2018-06-21 CL CL2018001716A patent/CL2018001716A1/es unknown
- 2018-06-22 ZA ZA2018/04229A patent/ZA201804229B/en unknown
- 2018-07-11 CO CONC2018/0007236A patent/CO2018007236A2/es unknown
-
2021
- 2021-04-08 US US17/226,004 patent/US20210347742A1/en active Pending
- 2021-08-31 JP JP2021141178A patent/JP7297828B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3394046A4 (en) | 2019-06-19 |
JP2018538352A (ja) | 2018-12-27 |
US20210347742A1 (en) | 2021-11-11 |
ES2913051T3 (es) | 2022-05-31 |
EP4071140A1 (en) | 2022-10-12 |
AU2016377785A1 (en) | 2018-07-12 |
EP3394046A1 (en) | 2018-10-31 |
PL3394046T3 (pl) | 2022-06-13 |
KR20180101416A (ko) | 2018-09-12 |
US20190031622A1 (en) | 2019-01-31 |
ZA201804229B (en) | 2021-10-27 |
JP2021185186A (ja) | 2021-12-09 |
RU2018126957A (ru) | 2020-01-27 |
RU2730855C2 (ru) | 2020-08-26 |
CL2018001716A1 (es) | 2018-10-26 |
EP3394046B1 (en) | 2022-03-09 |
CO2018007236A2 (es) | 2018-07-19 |
BR112018012934A2 (pt) | 2018-12-11 |
AU2016377785A2 (en) | 2018-08-23 |
JP7297828B2 (ja) | 2023-06-26 |
CA3009534A1 (en) | 2017-06-29 |
JP6938509B2 (ja) | 2021-09-22 |
US11084795B2 (en) | 2021-08-10 |
RU2018126957A3 (da) | 2020-02-28 |
CN108699040B (zh) | 2021-08-10 |
PT3394046T (pt) | 2022-04-05 |
IL260212B (en) | 2021-08-31 |
BR112018012934B1 (pt) | 2023-11-07 |
WO2017112950A1 (en) | 2017-06-29 |
AU2016377785B2 (en) | 2021-07-01 |
IL260212A (en) | 2018-07-31 |
CN108699040A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3265947T3 (da) | Fremgangsmåde og system til kryptering | |
DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3372034T3 (da) | Fremgangsmåder og indretning til planlægning i uplink | |
DK3346961T3 (da) | Anordning til stomi | |
DK3200615T3 (da) | Kaloriefrie sødestoffer og fremgangsmåder til syntetisering | |
DK3224603T3 (da) | Nordning og fremgangsmåde til materialekarakteristik | |
DK3319611T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
DK3260813T3 (da) | System og fremgangsmåde til afstandsbedømmelse | |
DK3270944T3 (da) | Optimerede leverspecifikke ekspressionssystemer til FVIII og FIX | |
DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
DK3265043T3 (da) | Hjælpemiddel til patienttransport og -træning | |
DK2983379T3 (da) | Systemer og fremgangsmåder til hørehjælps-rf-flerbåndsdrift | |
DK3129912T3 (da) | Fremgangsmåde og system til sikring af data | |
DK3072835T3 (da) | Fremgangsmåde til fremføring | |
DK3319612T3 (da) | Oxysteroler og fremgansmåder til anvendelse derfor | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3430038T3 (da) | Sammensætninger og fremgangsmåder til cd20-immunterapi | |
DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
DK3626602T3 (da) | Styreanordning og fremgangsmåde til styreanordningen | |
DK3234160T3 (da) | Sammensætninger og fremgangsmåder til hjælper-stamme-medieret svampegenommodifikation | |
DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
DK3436022T3 (da) | Oxysteroler og fremgangsmåder til anvendelse heraf | |
DK3304394T3 (da) | Fremgangsmåder og systemer til godkendelse | |
DK3256598T3 (da) | Svampestammer og anvendelsesfremgangsmåder |